Léa Payen

Dr. Léa Payen

Hospices Civils de Lyon, Lyon, Auvergne-Rhône-Alpes, France
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
JGJessica Garcia
Jessica Garcia
JFJulien Forestier
Julien Forestier
EDEric Dusserre
Eric Dusserre
AWAnne-Sophie WOZNY
Anne-Sophie WOZNY
FGFlorence Geiguer
Florence Geiguer
LPLéa Payen
Léa Payen
Cross-platform comparison for the detection of RAS mutations in cfDNA (ddPCR Biorad detection assay, BEAMing assay, and NGS strategy) Cross-platform comparison for the detection of RAS mutations in cfDNA (ddPCR Biorad detection assay, BEAMing assay, and NGS strategy)

1 June 2021 in ESMO Open
Verified
Journal Article
Open access
KHKhalil Hodroj
Khalil Hodroj
DBD. Barthelemy
D. Barthelemy
JLJ.-C. Lega
J.-C. Lega
GGG. Grenet
G. Grenet
MGM.-C. Gagnieu
M.-C. Gagnieu
LPLéa Payen
Léa Payen
Fluoropyrimidine-based chemotherapies are widely used to treat gastrointestinal tract, head and neck, and breast carcinomas. Severe toxicities mostly impact rapidly dividing cell lines and can occur due to the partial or complete deficiency in dihydropyrimidine dehydrogenase (DPD) catabolism. Since April 2020, the European Medicines Agency (EMA) recommends DPD testing before any fluoropyrimidine-based treatment. Currently, different assays are used to predict DPD deficiency; the two main approaches consist of either phenotyping the enzyme activity (directly or indirectly) or genotyping the four main deficiency-related polymorphisms associated with 5-fluorouracil (5-FU) toxicity. In this review, we focused on the advantages and limitations of these diagnostic methods: direct phenotyping by evaluation of peripheral mononuclear cell DPD activity (PBMC-DPD activity), indirect phenotyping assessed by uracil levels or UH2/U ratio, and genotyping DPD of four variants directly associated with 5-FU toxicity. The risk of 5-FU toxicity increases with uracil concentration. Having a pyrimidine-related structure, 5-FU is catabolised by the same physiological pathway. By assessing uracil concentration in plasma, indirect phenotyping of DPD is then measured. With this approach, in France, a decreased 5-FU dose is systematically recommended at a uracil concentration of 16 ng/ml, which may lead to chemotherapy under-exposure as uracil concentration is a continuous variable and the association between uracil levels and DPD activity is not clear. We aim herein to describe the different available strategies developed to improve fluoropyrimidine-based chemotherapy safety, how they are implemented in routine clinical practice, and the possible relationship with inefficacy mechanisms.

21 September 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
JGJessica Garcia
Jessica Garcia
EDEric Dusserre
Eric Dusserre
VCValérie Cheynet
Valérie Cheynet
PBPierre Paul Bringuier
Pierre Paul Bringuier
KBKaren Brengle-Pesce
Karen Brengle-Pesce
SCSébastien Couraud
Sébastien Couraud
Evaluation of pre-analytical conditions and comparison of the performance of several digital PCR assays for the detection of major EGFR mutations in circulating DNA from non-small cell lung cancers: the CIRCAN_0 study Evaluation of pre-analytical conditions and comparison of the performance of several Digital PCR assays for the detection of major EGFR mutations in circulating DNA from non-small cell lung cancers: the CIRCAN_0 study

15 December 2014 in Oncotarget
Verified
Journal Article
Open access
PDF file
MHMylène Honorat
Mylène Honorat
JGJérôme Guitton
Jérôme Guitton
CGCharlotte Gauthier
Charlotte Gauthier
CBCharlotte Bouard
Charlotte Bouard
FLFlorine Lecerf-Schmidt
Florine Lecerf-Schmidt
LPLéa Payen
Léa Payen
MBL-II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenografts MBL-II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenografts

9 July 2021 in Cells
Verified
Journal Article
Open access
PDF file
LDLucie Descamps
Lucie Descamps
MAMarie-Charlotte Audry
Marie-Charlotte Audry
JHJordyn Howard
Jordyn Howard
SMSamir Mekkaoui
Samir Mekkaoui
CAClément Albin
Clément Albin
ADAnne-Laure Deman
Anne-Laure Deman
Magnetophoresis-based microfluidic devices offer simple and reliable manipulation of micro-scale objects and provide a large panel of applications, from selective trapping to high-throughput sorting. However, the fabrication and integration of micro-scale magnets in microsystems involve complex and expensive processes. Here we report on an inexpensive and easy-to-handle fabrication process of micrometer-scale permanent magnets, based on the self-organization of NdFeB particles in a polymer matrix (polydimethylsiloxane, PDMS). A study of the inner structure by X-ray tomography revealed a chain-like organization of the particles leading to an array of hard magnetic microstructures with a mean diameter of 4 µm. The magnetic performance of the self-assembled micro-magnets was first estimated by COMSOL simulations. The micro-magnets were then integrated into a microfluidic device where they act as micro-traps. The magnetic forces exerted by the micro-magnets on superparamagnetic beads were measured by colloidal probe atomic force microscopy (AFM) and in operando in the microfluidic system. Forces as high as several nanonewtons were reached. Adding an external millimeter-sized magnet allowed target magnetization and the interaction range to be increased. Then, the integrated micro-magnets were used to study the magnetophoretic trapping efficiency of magnetic beads, providing efficiencies of 100% at 0.5 mL/h and 75% at 1 mL/h. Finally, the micro-magnets were implemented for cell sorting by performing white blood cell depletion.

5 May 2016 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
CBCharlotte Bouard
Charlotte Bouard
raphael terreuxraphael terreux
raphael terreux
MHMylène Honorat
Mylène Honorat
BMBrigitte Manship
Brigitte Manship
SAStéphane Ansieau
Stéphane Ansieau
LPLéa Payen
Léa Payen
The TWIST1 bHLH transcription factor controls embryonic development and cancer processes. Although molecular and genetic analyses have provided a wealth of data on the role of bHLH transcription factors, very little is known on the molecular mechanisms underlying their binding affinity to the E-box sequence of the promoter. Here, we used an in silico model of the TWIST1/E12 (TE) heterocomplex and performed molecular dynamics (MD) simulations of its binding to specific (TE-box) and modified E-box sequences. We focused on (i) active E-box and inactive E-box sequences, on (ii) modified active E-box sequences, as well as on (iii) two box sequences with modified adjacent bases the AT- and TA-boxes. Our in silico models were supported by functional in vitro binding assays. This exploration highlighted the predominant role of protein side-chain residues, close to the heart of the complex, at anchoring the dimer to DNA sequences, and unveiled a shift towards adjacent ((-1) and (-1*)) bases and conserved bases of modified E-box sequences. In conclusion, our study provides proof of the predictive value of these MD simulations, which may contribute to the characterization of specific inhibitors by docking approaches, and their use in pharmacological therapies by blocking the tumoral TWIST1/E12 function in cancers.